TEST:

PredicineALERT™

"Predicine...announced today that it will present data from 15 ctDNA studies at AACR 2024, spotlighting the clinical utility of Predicine’s genomic and epigenomic liquid biopsy solutions for patient selection, disease monitoring, and disease mechanism studies."

Conclusions Both tumor informed mutation based and tumor agnostic mehtylation based ctDNA approaches demonstrate clinical potential to monitor disease evolution and identify resistance prior to radiographic progression. Further study of such approaches to identify pre-radiographic molecular progression is warranted.

"Predicine...announced...that it will present two studies and introduce PredicineALERT™ Minimal Residual Disease (MRD) liquid biopsy assay to genitourinary (GU) cancers at the 2023 American Urological Association (AUA) Annual Meeting held in Chicago between April 28 to May 1, 2023...PredicineALERT™ provides a tumor-naive approach to MRD testing for GU cancers. Key highlights include methylation-based MRD detection without the need of personalization, fast turn-around-time (TAT) down to 6 days, and low sample input using 2.5ng of cfDNA."

"Predicine...announced today that it will present data from 12 studies and introduce PredicineALERT™, a next-generation Minimal Residual Disease (MRD) liquid biopsy assay at the 2023 AACR Conference on April 14-19, 2023....Key highlights of the PredicineALERT™ MRD assay include: (i) Tumor-naive MRD detection without the need of personalization; (ii) Fast turn-around-time (TAT) down to 6 days; (iii) Sample input using as low as 2.5ng cell-free DNA. Predicine will also present twelve posters demonstrating the clinical utility and effectiveness of Predicine’s liquid biopsy platform across a multitude of indications, clinical trials, and profiling applications."